LEN vs MIRM · rev $34.19B vs rev $336.9M
LEN (LEN) versus Mirum Pharmaceuticals Inc (MIRM) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Mirum Pharmaceuticals Inc (MIRM) is a biotechnology company listed on NASDAQ.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported MIRM revenue for 2024-12-31 was $336.9M. Net income was -$87.9M. Revenue was up 80.8% from 2023-12-31 to 2024-12-31. MIRM currently screens at market cap $6.22B.
LEN currently screens at market cap $0. MIRM currently screens at market cap $6.22B.
Not investment advice. Open the LEN and MIRM stock pages for the full models.
Not investment advice.